Summary

Your OPRM1 result determines how strongly your brain's opioid reward system responds to endorphins, social connection, and pain relief — the G allele reduces receptor function, meaning you need more to get the same effect, but it also means targeted interventions (exercise, social bonding, pain management) have outsized impact when done right.

Genotype spectrum

AA

Your reward system responds efficiently to natural endorphin triggers — exercise, social connection, laughter, physical touch. Standard opioid medication dosing is likely appropriate for you.

AG

You're sensitive enough to notice changes in your reward/pain landscape, which makes you a good self-monitor. You can detect when interventions are working or when something's off.

GG

Interventions that boost endorphin activity (vigorous exercise, social connection, specific stress management practices) have the highest potential impact for you because your baseline is lower. When these interventions work, the relative improvement is larger

Practical takeaway

For GG Carriers (Reduced Receptor — Priority)

Exercise as endorphin strategy:
• Vigorous exercise (above ~70% max HR) is the most potent natural endorphin stimulus. For you, the "runner's high" may take longer to achieve but is still accessible.
• Aim for at least 3-4 sessions per week of moderate-to-vigorous intensity. This isn't just fitness — it's neurochemical maintenance.
• Endurance exercise (30+ minutes) is more reliably endorphinogenic than short HIIT for most people. Experiment with duration vs. intensity.

Social connection as health behaviour:
• This isn't soft advice. Your biology responds more strongly to social isolation than AA carriers. Prioritise regular, meaningful social contact.
• Group exercise, team sports, and training partners serve double duty — exercise endorphins + social opioid release.
• If you tend toward social withdrawal under stress, recognise this as your biology pulling you away from something you actually need more of.

Pain management awareness:
• Inform anaesthesiologists and pain management providers about your OPRM1 status before any procedure.
• You may require 10-30% higher opioid doses for equivalent analgesia. This is not drug-seeking — it's pharmacogenomics.
• Explore non-opioid pain strategies proactively: NSAID pre-loading, regional anaesthesia, TENS, acupuncture (which triggers endogenous endorphin release through a different mechanism).

Alcohol awareness:
• Your alcohol reward processing is genetically altered. The evidence is mixed on direction, but the practical implication is clear: monitor your relationship with alcohol more carefully than average.
• If prescribed naltrexone for alcohol concerns, you may respond better than AA carriers (Anton et al. 2008 COMBINE data). Discuss with prescriber.

What "working" looks like:
• Regular exercise producing noticeable mood elevation (may take 4-6 weeks to establish pattern)
• Social connections maintained even during stressful periods
• Pain managed proactively rather than reactively
• Alcohol use intentional rather than compensatory

Expected response window: Exercise endorphin adaptation 4-8 weeks. Social bonding effects are ongoing. Pain management adjustments ar

Evidence detail

What This Gene Does

OPRM1 encodes the mu-opioid receptor — the primary receptor for endorphins, enkephalins, and opioid medications. This receptor sits at the heart of the brain's reward, pain, and social bonding systems. When endorphins bind to it, you experience pain relief, pleasure, social warmth, and stress reduction. The A118G variant (Asn40Asp) changes an asparagine to aspartate in the extracellular domain of the receptor, altering both its binding properties and its expression level.

The G allele reduces receptor expression by approximately 1.5-2x and alters beta-endorphin binding affinity. This isn't just about pain — the mu-opioid system mediates the rewarding aspects of social connection, the "runner's high" from exercise, and the pleasurable effects of alcohol. Changes in this receptor ripple through your entire reward and bonding landscape.

Mechanism

The mu-opioid receptor is the brain's primary interface for endorphin-mediated reward, pain modulation, and social bonding. Here's why A118G matters:

1. Endorphins are released during exercise, social connection, laughter, physical contact, and in response to pain and stress.
2. They bind to the mu-opioid receptor on neurons in the ventral tegmental area (VTA), nucleus accumbens, periaqueductal grey (pain), and amygdala (emotion).
3. The receptor signal produces pain relief, pleasure, stress reduction, and social bonding sensations.
4. The G allele reduces receptor density (~1.5-2x lower expression) in key brain regions. Fewer receptors means a higher threshold for endorphin-mediated effects.

The downstream consequences:
• Pain: Higher threshold for endorphin-mediated analgesia. More opioid medication needed for equivalent effect. Standard post-operative dosing may be insufficient.
• Reward: The pleasurable aspects of exercise, social connection, and (critically) alcohol are altered. The direction is debated — some studies suggest reduced reward, others suggest altered reward that may paradoxically increase seeking behaviour.
• Social bonding: The "social opioid" hypothesis (Machin & Dunbar 2011) proposes that endorphins cement social bonds. Reduced receptor function may increase sensitivity to social isolation and rejection — not because the person is "needy" but because the neurochemical mechanism that converts social contact into felt security is less efficient.
• Stress: HPA axis regulation is partially mediated by the opioid system. Altered receptor function shifts cortisol dynamics.

OPRM1 A118G

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (12)